Tag Archives: CRVS

Corvus Pharmaceuticals (CRVS) Received its Third Buy in a Row

After Wedbush and Mizuho Securities gave Corvus Pharmaceuticals (NASDAQ: CRVS) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Swayampakula Ramakanth reiterated a Buy rating on Corvus Pharmaceuticals today and set a price

Mizuho Securities Keeps a Buy Rating on Corvus Pharmaceuticals (CRVS)

In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Corvus Pharmaceuticals (CRVS – Research Report), with a price target of $7.00. The company’s shares closed last Thursday at $4.27. According to TipRanks.com, Goldstein ‘s

Corvus Pharmaceuticals (CRVS) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Corvus Pharmaceuticals (CRVS – Research Report) yesterday and set a price target of $7.00. The company’s shares closed last Thursday at $2.43. According to TipRanks.com, Goldstein is a 1-star analyst

Mizuho Securities Keeps a Buy Rating on Corvus Pharmaceuticals Inc (CRVS)

In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Corvus Pharmaceuticals Inc (CRVS – Research Report), with a price target of $7.00. The company’s shares closed last Monday at $3.66. According to TipRanks.com, Goldstein

Mizuho Securities Sticks to Its Buy Rating for Corvus Pharmaceuticals Inc (CRVS)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Corvus Pharmaceuticals Inc (CRVS – Research Report), with a price target of $7. The company’s shares closed last Monday at $4.15, close to its 52-week

Cowen & Co. Keeps Their Buy Rating on Corvus Pharmaceuticals Inc (CRVS)

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Corvus Pharmaceuticals Inc (NASDAQ: CRVS) today. The company’s shares closed yesterday at $8.20. According to TipRanks.com, Peaker is a 4-star analyst with an average return of 8.3% and a